Sangamo Therapeutics files prospectus supplement for up to $204M in ATM sales

SANGAMO THERAPEUTICS, INC

Remaining ATM capacity of $204.1M under $325M Sales Agreement with Jefferies LLC as of March 7, 2023.
Filed Amendment No. 3 to the Open Market Sale Agreement to reflect the remaining shares.
Filed legal opinion from Cooley LLP on validity of the common stock offered.

item 8.01 item 9.01

SANGAMO THERAPEUTICS, INC filing history →

Source: SEC EDGAR

accession 0001628280-23-006626

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.